Key result
This review summarizes genetic mutations associated with cardiomyopathy and the roles of epigenetic mechanisms, including DNA methylation and microRNA, in heart failure.
This review highlights the role of genetic mutations and epigenetic regulation in heart failure, suggesting potential avenues for individualized therapies and surveillance.
May guide personalized cardiomyopathy research; leaves open clinical adoption of genetic-epigenetic screening pending prospective trials.
Heart failure (HF) is a complex pathophysiological syndrome that arises from a primary defect in the ability of the heart to take in and/or eject sufficient blood. Genetic mutations associated with familial dilated cardiomyopathy, hypertrophic cardiomyopathy, and arrhythmogenic right ventricular cardiomyopathy can contribute to the various pathologies of HF. Therefore, genetic screening could be an approach for guiding individualized therapies and surveillance. In addition, epigenetic regulation occurs via key mechanisms, including ATP-dependent chromatin remodeling, DNA methylation, histone modification, and RNA-based mechanisms. MicroRNA is also a hot spot in HF research. This review gives an overview of genetic mutations associated with cardiomyopathy and the roles of some epigenetic mechanisms in HF.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2015) conducted a review in Heart failure. Genetic mutations and epigenetic mechanisms was evaluated. This review summarizes genetic mutations associated with cardiomyopathy and the roles of epigenetic mechanisms, including DNA methylation and microRNA, in heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: